IRAG
FTH

Investment Research & Advisory Group’s Faeth Therapeutics FTH Stock Holding History

Investment Research & Advisory Group’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-70
Closed -$4K – 198
2021
Q4 		$4K Hold
70
– – ﹤0.01% 180
2021
Q3 		$5K Buy
+70
New +$12.7K ﹤0.01% 138

Other funds holding FTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Investment Research & Advisory Group's FTH Position: Q1 2022 in Review

Investment Research & Advisory Group sold out of Faeth Therapeutics (FTH) in Q1 2022, closing a stake of 70 shares — an estimated $4K sold.

Investment Research & Advisory Group first reported a position in FTH in Q3 2021 and held it in 2 quarters. The position peaked at $5K in Q3 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q1 2022.

  • Investment Research & Advisory Group reported no remaining Faeth Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Investment Research & Advisory Group sold 70 Faeth Therapeutics shares in Q1 2022, an estimated $4K.
  • Investment Research & Advisory Group first reported a position in Faeth Therapeutics in Q3 2021 and held it in 2 quarters.
  • Investment Research & Advisory Group's Faeth Therapeutics position peaked at $5K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2022.

Based on Investment Research & Advisory Group's 13F filing for Q1 2022, filed 25 Apr 2022.